Los Angeles, CA 2080 Century Park East Suite 710 Los Angeles, CA 90067

Provider \_\_\_\_\_





Office: 310-481-9944 Fax: 310-766-7001

Provider Order Form

Inebilizumab-cdon	(Uplizna)	Date:
-------------------	-----------	-------

	PATIENT INFORMATION			
_	lame:	DOB:		
_	llergies:	Date of Referral: .		
	inergies.	Date of Referral.		
ICI	D-10 code (required):	ICD -10 description:		
	NKDA Allergies:	Weight lbs/kg:		
Pa	tient Status: $\square$ New to Therapy $\square$ Continuing T	herapy Next Due Date (if applicable) :□ Dose/Frequency Change □ Discontinuation Order		
		PROVIDER INFORMATION		
Re	ferral Coordinator Name:	Referral Coordinator Email:		
Or	dering Provider:	Provider NPI:		
Re	ferring Practice Name:	Phone: Fax:		
Pra	actice Address:	City: State: Zip Code:		
N	JRSING	LABORATORY ORDERS		
Ø	Provide nursing care per IVX Nursing Proced reaction management and post-procedure ob NOTE: IVX Adverse Reaction Management P for review at <a href="https://www.ivxhealth.com/forms">www.ivxhealth.com/forms</a> (vers	ervation		
Ø	Tuberculosis status and date (list results here	& attach clinicals)  THERAPY ADMINISTRATION  ☐ Inebilizumab-cdon (Uplizna) intravenous infusion. Dose: ☐Other_		
Ø	Quantitative serum immunoglobulin (list resu attach clinicals):	Its here & Induction:  Dose: 300mg in 250ml 0.9% sodium chloride Frequency: on Day 1 and Day 15		
V	Hepatitis B status & date (list results here & a	tach clinicals):  Rate: Start at 42ml/hr x30 min, 125ml/hr x 30 min, then 333ml/hr for remainder of infusion		
PR	EN-MEDICATION ORDERS	<ul> <li>Duration should be approximately 90 minutes</li> <li>Administer through an intravenous line containing a sterile</li> </ul>		
V V	acetaminophen (Tylenol) 650mg PO diphenhydramine 50mg PO	<ul> <li>low-protein binding 0.2 or 0.22 micron in-line filter.</li> <li>After induction, continue with maintenance dosing below</li> </ul>		
Ø	methylprednisolone (Solu-Medrol) 125mg IV	☐ Maintenance:		
	cetirizine (Zyrtec) 10mg PO loratadine (Claritin) 10mg PO famotidine (Pepcid) 20mg PO Other: Route: Rrequency:			
		nd tuberculosis screening is required before the first dose.   Prior to every infusion premedicate c.   Monitor patients closely during and for at least one hour after infusion.		
Pro	ovider Name (Print)	Provider Signature Date		
Ol	RDERING PROVIDER			
Çi,	gnature $X$	Date		
JIE	griature <u>A</u>	Date		

Phone Fax \_\_\_